The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries
A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 445 participants.
Also called NCT04192747
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 445 participants
- Sponsor
- Registry
-
NCT04192747
-
- Other papers using this trial's data
- Percutaneous Coronary Treatment With Bioadaptor Implant vs Drug-Eluting Stent: 2-Year Outcomes From BIOADAPTOR RCT
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Results first posted
- Countries
- Belgium, Germany, Japan, New Zealand
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT04192747. Randomized; double masking; primary purpose treatment. Start 2020-12-16 (actual); primary completion 2023-02-28 (actual). Results posted on 2024-10-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries
- Acronym
- BIOADAPTOR RCT
- Condition
- Coronary Artery Disease
- Condition
- Coronary Artery Stenosis
- Condition
- Coronary Disease
- Condition
- Coronary Stenosis
- Intervention (Device)
- Percutaneous Coronary Intervention
- Lead sponsor
- Elixir Medical Corporation
Record details
- Record id
cardio:ct-nct04192747- Content hash
271993634da79808748e00abd87df4c6661ac487db765e1fcb46f10eaae09d4c